BioXcel Therapeutics, Inc. (BTAI) financial statements (2020 and earlier)

Company profile

Business Address 555 LONG WHARF DRIVE
NEW HAVEN, CT 06511
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4043
Cash and cash equivalents4043
Receivables 0
Other undisclosed current assets10
Total current assets:4143
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment10
Other noncurrent assets00
Total noncurrent assets:20
TOTAL ASSETS:4444
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities85
Accounts payable42
Accrued liabilities33
Other liabilities1 
Other undisclosed current liabilities0 
Total current liabilities:85
Noncurrent Liabilities
Long-term debt and lease obligation1 
Operating lease, liability1
Total noncurrent liabilities:1 
Total liabilities:95
Stockholders' equity
Stockholders' equity attributable to parent3439
Common stock00
Additional paid in capital8363
Accumulated deficit(48)(24)
Total stockholders' equity:3439
TOTAL LIABILITIES AND EQUITY:4444

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
Operating expenses(33)(20)
Operating loss:(33)(20)
Loss before gain (loss) on sale of properties:(33)(20)
Other undisclosed net income01
Net loss:(32)(19)
Other undisclosed net income attributable to parent0 
Net loss available to common stockholders, diluted:(32)(19)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
Net loss:(32)(19)
Comprehensive loss, net of tax, attributable to parent:(32)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: